



RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/398,365

DATE: 1999-09-17

TIME: 14:17

Input File : N:\Crf3\RULE60\09398365.RAW.txt

Output File : N:\CRF4\06022003\I398365.raw

SEQUENCE LISTING

3 (i) GENERAL INFORMATION:

4 (i) APPLICANT: Baveland, David
 5 Baistran, John
 6 Johansen, II
 7 Anderson, Asger Olaf
 8 Markussen, Ole

11 (ii) TITLE OF INVENTION: ACTIVATED INHIBIN

13 (iii) NUMBER OF SEQUENCES: 40

15 (iv) CORRESPONDENT ADDRESS:

16 (A) ADDRESSEE: Novo Nordisk of North America, Inc.
 17 (B) STREET: 401 Lexington Avenue, 64th Floor
 18 (C) CITY: New York
 19 (D) STATE: New York
 20 (E) COUNTRY: United States of America
 21 (F) ZIP: 10174-6401

23 (v) COMPUTER READABLE FORM:

24 (A) MEDIUM TYPE: Floppy disk
 25 (B) COMPUTER: IBM PC compatible
 26 (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 27 (D) SOFTWARE: PatentIn Release #1.0, Version #1.1

29 (vi) CURRENT APPLICATION DATA:

C--> 30 (A) APPLICATION NUMBER: US/09/398,365

C--> 31 (B) FILING DATE: 17-Sep-1999

32 (C) CLASSIFICATION:

35 (vii) PRIOR APPLICATION DATA:

36 (A) APPLICATION NUMBER: US/08/460,256

37 (B) FILING DATE: 03-MAR-1998

39 (viii) ATTORNEY/AGENT INFORMATION:

40 (A) NAME: Smith, Paul
 41 (B) REGISTRATION NUMBER: 11,111
 42 (C) REFERENCE: 11,111

43 (ix) CONTACT INFORMATION:

44 (A) TELEPHONE: 11-111-1111
 45 (B) TELEFAX: 11-111-1111

47 (x) INFORMATION FOR SEQ. 1: 1:

48 (A) SEQUENCE CHARACTERISTICS:

49 (B) LENGTH: 1111111111

50 (C) TYPE: 1111111111

ENTERED

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/398,365

DATE: 11/11/03
TIME: 14:51:00

Seq. ID NO.: N:\Crif3\RULE60\09398365.RAW.txt

Seq. ID NO.: N:\CRF4\06022003\I398365.raw

```

61      1
W--> 64      Glu Asn Tyr Cys Xaa
65      20
66 (1) INFORMATION FOR SEQ ID NO: 1:
67 (i) SEQUENCE CHARACTERISTICS:
68 (A) LENGTH: 20 amino acids
69 (B) TYPE: amino acid
70 (C) STRANDEDNESS: linear
71 (D) TOPOLOGY: linear
72 (ii) MOLECULE TYPE: protein
73 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
W--> 79      Xaa Val Xaa Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr
80      1          5          10          15
81      Ser Val Tyr Gly Ala Asn Gly Ile Ile Tyr Thr Pro Lys Xaa
82      16          20          25          30
83 (2) INFORMATION FOR SEQ ID NO: 3:
84 (i) SEQUENCE CHARACTERISTICS:
85 (A) LENGTH: 111 base pairs
86 (B) TYPE: nucleic acid
87 (C) STRANDEDNESS: single
88 (D) TOPOLOGY: linear
W--> 94      (ii) MOLECULE TYPE: DNA
95 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
96 TGCTTAAGAG AATGCTTGAC CAAGACTTAT GGTGTTCTCA GTTGTTGAA AGTTTGAT 60
97 TGGTTGTTGG TAAAGAGAGT TTCTTCTACA CTCAAGAGTC TGACGACGCT 110
98 (4) INFORMATION FOR SEQ ID NO: 4:
99 (i) SEQUENCE CHARACTERISTICS:
100 (A) LENGTH: 111 base pairs
101 (B) TYPE: nucleic acid
102 (C) STRANDEDNESS: single
103 (D) TOPOLOGY: linear
W--> 111      (ii) MOLECULE TYPE: DNA
112 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
113 CTGCGGGGCTG CCTCTAAGCA CAGTAGTTTT CCAATTGGTA CAAAGAACAG ATAGAAGTAC 60
114 AAGATGTTTC AAGGATACCC TTACGCTGCT CAAGTTTGG 110
115 (5) INFORMATION FOR SEQ ID NO: 5:
116 (i) SEQUENCE CHARACTERISTICS:
117 (A) LENGTH: 111 base pairs
118 (B) TYPE: nucleic acid
119 (C) STRANDEDNESS: single
120 (D) TOPOLOGY: linear
W--> 128      (ii) MOLECULE TYPE: DNA
129 (iii) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
130 TAAAGATGTTT CAAAGGATACCTT 111
131 (6) INFORMATION FOR SEQ ID NO: 6:
132 (i) SEQUENCE CHARACTERISTICS:
133 (A) LENGTH: 111 base pairs
134 (B) TYPE: nucleic acid
135 (C) STRANDEDNESS: single
136 (D) TOPOLOGY: linear

```

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/398,365

DATE: 01/11/2000
TIME: 14:11

Input File: N:\Crif3\RULE60\09398365.RAW.txt

Input Seq: N:\CRF4\06022003\I398365.raw

```

W--> 143      (ii) MOLECULE TYPE: DNA
145      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:
147 CTGTTTAAATGATGCGGGGC TCGGTCT
149 (2) INFORMATION FOR SEQ ID NO: 6:
151      (i) SEQUENCE CHARACTERISTICS:
153          (A) LENGTH: 11 base pairs
154          (B) TYPE: nucleic acid
155          (C) STRANDEDNESS: single
156          (D) TOPOLOGY: linear

W--> 158      (ii) MOLECULE TYPE: DNA
160      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:
161 TTTATTAAGGATGTTTACT CAAGATTTT GGGTTTCTA CTTCCTTAA GTTTCTACT
163 TGGTTTCTTGAAGAGAGGT TTCTTCTATA CTGTAAGTGT TGAGCAAGCT
165 (2) INFORMATION FOR SEQ ID NO: 7:
167      (i) SEQUENCE CHARACTERISTICS:
170          (A) LENGTH: 25 base pairs
171          (B) TYPE: nucleic acid
172          (C) STRANDEDNESS: single
173          (D) TOPOLOGY: linear

W--> 175      (ii) MOLECULE TYPE: DNA
177      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:
179 TTGAGCATGG CTAAGAGATT CGTTA
181 (2) INFORMATION FOR SEQ ID NO: 9:
183      (i) SEQUENCE CHARACTERISTICS:
186          (A) LENGTH: 100 base pairs
187          (B) TYPE: nucleic acid
188          (C) STRANDEDNESS: single
189          (D) TOPOLOGY: linear

W--> 190      (ii) MOLECULE TYPE: DNA
192      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:
194 TTTTATTTT TTTTAAATA CATTATTTT TCAATTTTA GAGG TTTTATTTT TTTT
196 AAATTTTTC AACGATATTC TTAGCTTCTT TAAATTTTC
198 (2) INFORMATION FOR SEQ ID NO: 10:
200      (i) SEQUENCE CHARACTERISTICS:
203          (A) LENGTH: 17 base pairs
204          (B) TYPE: nucleic acid
205          (C) STRANDEDNESS: single
206          (D) TOPOLOGY: linear

W--> 207      (ii) MOLECULE TYPE: DNA
209      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:
211 AATATATTTT TAAATATTC GAGCTAT
213 (2) INFORMATION FOR SEQ ID NO: 11:
215      (i) SEQUENCE CHARACTERISTICS:
218          (A) LENGTH: 16 base pairs
219          (B) TYPE: nucleic acid
220          (C) STRANDEDNESS: single
221          (D) TOPOLOGY: linear

```


^a The number of subjects who were included in each group.

Figure 1. The effect of the concentration of the *Agrobacterium* suspension on the transformation efficiency of *Agrobacterium* strains.

Input File : N:\Crf3\RULE60\09398365.RAW.txt

File Name : N:\CRF4\06022003\I398365.raw

[illegible]

13 170 INFORMATION FOR SEQ ID NO: 15:

515 (i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 104 AMPLIF. 01148

(4) TYPE: amino acid

(D) TOPOLOGY: linear

(11) MOLECULE TYPE: prot. in

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

324 Met Lys Ala Val Phe Leu Val Leu Ser Leu Ile Gly Phe Cys Trp Ala

427 Gln Pro Val Thr Gly Asp Glu Ser Ser Val Glu Ile Pro Glu Glu Ser

229 20 23 30

136 Leu Ile Ile Ala Glu Asp Thr Thr Leu Ala Asp Val Ala Met Ala Lys

133 Arg Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu

536 Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ser Asp

| | | | | |
|-----|----|----|----|----|
| 537 | 65 | 70 | 75 | 80 |
|-----|----|----|----|----|

199 Asp Ala Lys Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Lys

[illegible][illegible]

746 (2) INFORMATION FOR SEO ID NO: 16:

(2) SEQUENCE CHARACTERISTICS:

THE UNIVERSITY OF CHICAGO PRESS

(iv) Type: nucleic acid

551 (C) STRANDEDNESS: single

152 (D) TOPOLOGY: 11494

W--> 354 (ii) MOLECULE TYPE: DNA

(11) POLYMER TYPE: DMI

(12) SUBMITTER INFORMATION: M. J. HARRIS : 61:

^a The number of subjects who were included in each group was 10.

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | 209 | 210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | 289 | 290 | 291 | 292 | 293 | 294 | 295 | 296 | 297 | 298 | 299 | 300 | 301 | 302 | 303 | 304 | 305 | 306 | 307 | 308 | 309 | 310 | 311 | 312 | 313 | 314 | 315 | 316 | 317 | 318 | 319 | 320 | 321 | 322 | 323 | 324 | 325 | 326 | 327 | 328 | 329 | 330 | 331 | 332 | 333 | 334 | 335 | 336 | 337 | 338 | 339 | 340 | 341 | 342 | 343 | 344 | 345 | 346 | 347 | 348 | 349 | 350 | 351 | 352 | 353 | 354 | 355 | 356 | 357 | 358 | 359 | 360 | 361 | 362 | 363 | 364 | 365 | 366 | 367 | 368 | 369 | 370 | 371 | 372 | 373 | 374 | 375 | 376 | 377 | 378 | 379 | 380 | 381 | 382 | 383 | 384 | 385 | 386 | 387 | 388 | 389 | 390 | 391 | 392 | 393 | 394 | 395 | 396 | 397 | 398 | 399 | 400 | 401 | 402 | 403 | 404 | 405 | 406 | 407 | 408 | 409 | 410 | 411 | 412 | 413 | 414 | 415 | 416 | 417 | 418 | 419 | 420 | 421 | 422 | 423 | 424 | 425 | 426 | 427 | 428 | 429 | 430 | 431 | 432 | 433 | 434 | 435 | 436 | 437 | 438 | 439 | 440 | 441 | 442 | 443 | 444 | 445 | 446 | 447 | 448 | 449 | 450 | 451 | 452 | 453 | 454 | 455 | 456 | 457 | 458 | 459 | 460 | 461 | 462 | 463 | 464 | 465 | 466 |
|---|---|---|---|---|---|---|---|---|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|

1. *Pharmaceutical industry* – The pharmaceutical industry is the largest of the three industries, with sales of 10.5 billion dollars in 1997. It is the only industry that has been able to maintain its market share in the face of a declining market. The industry is characterized by a high degree of concentration, with the top five firms accounting for 40% of sales. The industry is also characterized by a high degree of innovation, with a large number of new drugs being developed each year. The industry is facing a number of challenges, including a declining market, a high degree of competition, and a high degree of regulation.

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION N: US/09/398,365

DATE: 09/10/2009
TIME: 14:11:11

Input File : N:\Crf3\RULE60\09398365.RAW.txt
Output File : N:\CRF4\06022003\I398365.raw

Please Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one n or Xaa.

Seq#1; Xaa 1 to 20
Seq#1; Xaa Pcs.1, 1, 40

VERIFICATION SUMMARY

PATENT APPLICATION: US/09/398,365

DATE: 11/11/2009
TIME: 17:41:00

Input File : N:\Crif3\RULE60\09398365.RAW.txt

Output File : N:\CRF4\06022003\I398365.raw

L:1 M:246 W: Keyword misspelled or invalid format, [PAT] APPLICATION NUMBER:
 L:1 M:246 W: Keyword misspelled or invalid format, [IP] FILING DATE:
 L:64 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#1 after pos:10
 L:78 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#1 after pos:10
 M:341 Repeated in SeqNo:2
 L:84 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 3
 L:111 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 4
 L:128 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 5
 L:144 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 6
 L:158 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 7
 L:175 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 8
 L:190 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 9
 L:207 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 10
 L:222 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 11
 L:239 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 12
 L:256 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 13
 L:274 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 16
 L:279 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 19
 L:292 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 2
 L:701 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 25
 L:610 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 28
 L:819 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 31
 L:1043 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 34
 L:1156 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 37
 L:1260 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 40
 L:1409 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 43
 L:1541 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 46
 L:1601 M:246 W: Invalid value of Alpha Sequence Header Field, [MOLECULE TYPE:], SeqNo: 49